Metabolic Myopathies

Abstract

Metabolic myopathies encompass a group of rare disorders arising from defects in glycogen breakdown (glycogenolysis), glucose utilization (glycolysis), fatty acid transport and oxidation, and energy production along the mitochondrial respiratory chain. The authors review the ancillary testing used in the workup of metabolic myopathies and provide a detailed discussion of these individual disorders and how to approach patients suspected to have such diagnoses.

Keywords

metabolic myopathy - glycogen storage disease - lipid metabolism - fatty acid oxidation - mitochondrial myopathy

• References

• 1 Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22 (2) 87-97
• 2 Tarnopolsky MA. What can metabolic myopathies teach us about exercise physiology?. Appl Physiol Nutr Metab 2006; 31 (1) 21-30
• 3 Dougherty FE. Metabolic testing in mitochondrial disease. Semin Neurol 2001; 21 (3) 303-308
• 4 Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing J. A nonischemic forearm exercise test for McArdle disease. Ann Neurol 2002; 52 (2) 153-159
• 5 Hogrel JY, Laforêt P, Ben Yaou R, Chevrot M, Eymard B, Lombès A. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001; 56 (12) 1733-1738
• 6 Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med 2008; 10 (2) 151-156
• 7 Lucia A, Ruiz JR, Santalla A , et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry 2012; 83 (3) 322-328
• 8 Quinlivan R, Buckley J, James M , et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry 2010; 81 (11) 1182-1188
• 9 Vieitez I, Teijeira S, Fernandez JM , et al. Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Identification of 20 novel mutations. Neuromuscul Disord 2011; 21 (12) 817-823
• 10 Vissing J, Haller RG. A diagnostic cycle test for McArdle's disease. Ann Neurol 2003; 54 (4) 539-542
• 11 Haller RG, Vissing J. Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease: oxidative mechanisms. Arch Neurol 2002; 59 (9) 1395-1402
• 12 Nadaj-Pakleza AA, Vincitorio CM, Laforêt P , et al. Permanent muscle weakness in McArdle disease. Muscle Nerve 2009; 40 (3) 350-357
• 13 Witting N, Duno M, Piraud M, Vissing J. Severe axial myopathy in McArdle disease. JAMA Neurol 2014; 71 (1) 88-90
• 14 Martinuzzi A, Schievano G, Nascimbeni A, Fanin M. McArdle's disease. The unsolved mystery of the reappearing enzyme. Am J Pathol 1999; 154 (6) 1893-1897
• 15 Sugie H, Sugie Y, Ito M, Fukuda T, Nonaka I, Igarashi Y. Genetic analysis of Japanese patients with myophosphorylase deficiency (McArdle's disease): single-codon deletion in exon 17 is the predominant mutation. Clin Chim Acta 1995; 236 (1) 81-86
• 16 de Luna N, Brull A, Lucia A , et al. PYGM expression analysis in white blood cells: a complementary tool for diagnosing McArdle disease?. Neuromuscul Disord 2014; 24 (12) 1079-1086
• 17 Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev 2010; (12) CD003458
• 18 Musumeci O, Bruno C, Mongini T , et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord 2012; 22 (4) 325-330
• 19 Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 2004; 62 (1) 82-86
• 20 Nakajima H, Raben N, Hamaguchi T, Yamasaki T. Phosphofructokinase deficiency; past, present and future. Curr Mol Med 2002; 2 (2) 197-212
• 21 Malfatti E, Birouk N, Romero NB , et al. Juvenile-onset permanent weakness in muscle phosphofructokinase deficiency. J Neurol Sci 2012; 316 (1–2) 173-177
• 22 Vives-Corrons JL, Koralkova P, Grau JM, Mañú Pereira MdelM, Van Wijk R. First description of phosphofructokinase deficiency in spain: identification of a novel homozygous missense mutation in the PFKM gene. Front Phys 2013; 4: 393
• 23 DiMauro S, Spiegel R. Progress and problems in muscle glycogenoses. Acta Myol 2011; 30 (2) 96-102
• 24 Bak H, Cordato D, Carey WF, Milder D. Adult-onset exercise intolerance due to phosphorylase b kinase deficiency. J Clin Neurosci 2001; 8 (3) 286-287
• 25 Ørngreen MC, Schelhaas HJ, Jeppesen TD , et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?. Neurology 2008; 70 (20) 1876-1882
• 26 Preisler N, Orngreen MC, Echaniz-Laguna A , et al. Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease?. Neurology 2012; 78 (4) 265-268
• 27 Wilkinson DA, Tonin P, Shanske S, Lombes A, Carlson GM, DiMauro S. Clinical and biochemical features of 10 adult patients with muscle phosphorylase kinase deficiency. Neurology 1994; 44 (3 Pt 1): 461-466
• 28 Burwinkel B, Maichele AJ, Aagenaes O , et al. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB). Hum Mol Genet 1997; 6 (7) 1109-1115
• 29 Spiegel R, Gomez EA, Akman HO, Krishna S, Horovitz Y, DiMauro S. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord 2009; 19 (3) 207-211
• 30 Aasly J, van Diggelen OP, Boer AM, Brønstad G. Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms. Eur J Neurol 2000; 7 (1) 111-113
• 31 DiMauro S, Dalakas M, Miranda AF. Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol 1983; 13 (1) 11-19
• 32 Spanu C, Oltean S. Familial phosphoglycerate kinase deficiency associated with rhabdomyolysis and acute renal failure: abnormality in mRNA splicing?. Nephrol Dial Transplant 2003; 18 (2) 445-446
• 33 Sotiriou E, Greene P, Krishna S, Hirano M, DiMauro S. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve 2010; 41 (5) 707-710
• 34 Naini A, Toscano A, Musumeci O, Vissing J, Akman HO, DiMauro S. Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol 2009; 66 (3) 394-398
• 35 Tsujino S, Shanske S, Sakoda S, Fenichel G, DiMauro S. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet 1993; 52 (3) 472-477
• 36 Oh SJ, Park KS, Ryan Jr HF , et al. Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency. Muscle Nerve 2006; 34 (5) 572-576
• 37 Joshi PR, Knape M, Zierz S, Deschauer M. Phosphoglycerate mutase deficiency: case report of a manifesting heterozygote with a novel E154K mutation and very late onset. Acta Neuropathol 2009; 117 (6) 723-725
• 38 Tonin P, Bruno C, Cassandrini D , et al. Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene. Neuromuscul Disord 2009; 19 (11) 776-778
• 39 Yoshikuni K, Tagami H, Yamada M, Sudo K, Kanno T. Erythematosquamous skin lesions in hereditary lactate dehydrogenase M-subunit deficiency. Arch Dermatol 1986; 122 (12) 1420-1424
• 40 Anai T, Urata K, Tanaka Y, Miyakawa I. Pregnancy complicated with lactate dehydrogenase M-subunit deficiency: the first case report. J Obstet Gynaecol Res 2002; 28 (2) 108-111
• 41 Takahashi Y, Miyajima H, Kaneko E. Genetic analysis of a family of lactate dehydrogenase A subunit deficiency. Intern Med 1995; 34 (5) 326-329
• 42 Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutake K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta 1988; 173 (1) 89-98
• 43 Kreuder J, Borkhardt A, Repp R , et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 1996; 334 (17) 1100-1104
• 44 Yao DC, Tolan DR, Murray MF , et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood 2004; 103 (6) 2401-2403
• 45 Comi GP, Fortunato F, Lucchiari S , et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 2001; 50 (2) 202-207
• 46 Tegtmeyer LC, Rust S, van Scherpenzeel M , et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 2014; 370 (6) 533-542
• 47 Stojkovic T, Vissing J, Petit F , et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 2009; 361 (4) 425-427
• 48 Haller REA. Phosphoglucomutase (PGM 1) deficiency: a novel defect of muscle glycogen degradation and synthesis (P07.200). Neurology 2012; 78 (Meeting Abstracts 1): P07.200
• 49 van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008; 372 (9646) 1342-1353
• 50 American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve 2009; 40 (1) 149-160
• 51 van der Beek NA, de Vries JM, Hagemans ML , et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 2012; 7: 88
• 52 Schüller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet 2012; 160C (1) 80-88
• 53 Salem B, Thaisetthawatkul P, Fernandes JA, McComb RD. Adult-onset acid maltase deficiency with isolated axial muscle involvement. J Clin Neuromuscul Dis 2010; 12 (1) 30-35
• 54 Spada M, Porta F, Vercelli L , et al. Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia. Mol Genet Metab 2013; 109 (2) 171-173
• 55 Jones Jr LK, Liewluck T, Gavrilova RH. Myalgic phenotype and preserved muscle strength in adult-onset acid maltase deficiency. Neuromuscul Disord 2012; 22 (8) 763-766
• 56 Winkel LP, Hagemans ML, van Doorn PA , et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005; 252 (8) 875-884
• 57 Müller-Felber W, Horvath R, Gempel K , et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007; 17 (9–10) 698-706
• 58 Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol 2010; 257 (10) 1730-1733
• 59 Beltran Papsdorf TB, Howard Jr JF, Chahin N. Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency. Neurology 2014; 82 (9) e73-e75
• 60 Cupler EJ, Berger KI, Leshner RT , et al; AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012; 45 (3) 319-333
• 61 Anderson LJ, Henley W, Wyatt KM , et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014; 37 (6) 945-952
• 62 Kishnani PS, Austin SL, Arn P , et al; ACMG. Glycogen storage disease type III diagnosis and management guidelines. Genet Med 2010; 12 (7) 446-463
• 63 Cornelio F, Bresolin N, Singer PA, DiMauro S, Rowland LP. Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol 1984; 41 (10) 1027-1032
• 64 DiMauro S, Hartwig GB, Hays A , et al. Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 1979; 5 (5) 422-436
• 65 Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS. The electrodiagnostic characteristics of Glycogen Storage Disease Type III. Genet Med 2010; 12 (7) 440-445
• 66 Bruno C, Cassandrini D, Assereto S, Akman HO, Minetti C, Di Mauro S. Neuromuscular forms of glycogen branching enzyme deficiency. Acta Myol 2007; 26 (1) 75-78
• 67 Li SC, Hwu WL, Lin JL , et al. Association of the congenital neuromuscular form of glycogen storage disease type IV with a large deletion and recurrent frameshift mutation. J Child Neurol 2012; 27 (2) 204-208
• 68 Klein CJ, Boes CJ, Chapin JE , et al. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome. Muscle Nerve 2004; 29 (2) 323-328
• 69 Mochel F, Schiffmann R, Steenweg ME , et al. Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol 2012; 72 (3) 433-441
• 70 Joshi PR, Deschauer M, Zierz S. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. J Neurol Sci 2014; 338 (1–2) 107-111
• 71 Fanin M, Anichini A, Cassandrini D , et al. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet 2012; 82 (3) 232-239
• 72 Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005; 62 (1) 37-41
• 73 Gempel K, Kiechl S, Hofmann S , et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 2002; 25 (1) 17-27
• 74 Corti S, Bordoni A, Ronchi D , et al. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J Neurol Sci 2008; 266 (1–2) 97-103
• 75 Al-Thihli K, Sinclair G, Sirrs S, Mezei M, Nelson J, Vallance H. Performance of serum and dried blood spot acylcarnitine profiles for detection of fatty acid β-oxidation disorders in adult patients with rhabdomyolysis. J Inherit Metab Dis 2014; 37 (2) 207-213
• 76 Laforêt P, Vianey-Saban C, Vissing J. 162nd ENMC International Workshop: Disorders of muscle lipid metabolism in adults 28-30 November 2008, Bussum, The Netherlands. Neuromuscul Disord 2010; 20 (4) 283-289
• 77 Vockley J, Whiteman DA. Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul Disord 2002; 12 (3) 235-246
• 78 Bonnefont JP, Bastin J, Laforêt P , et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010; 88 (1) 101-108
• 79 Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 2014; 82 (7) 607-613
• 80 Ohashi Y, Hasegawa Y, Murayama K , et al. A new diagnostic test for VLCAD deficiency using immunohistochemistry. Neurology 2004; 62 (12) 2209-2213
• 81 Laforêt P, Acquaviva-Bourdain C, Rigal O , et al. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord 2009; 19 (5) 324-329
• 82 Spiekerkoetter U, Bennett MJ, Ben-Zeev B, Strauss AW, Tein I. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29 (1) 66-72
• 83 Schaefer J, Jackson S, Dick DJ, Turnbull DM. Trifunctional enzyme deficiency: adult presentation of a usually fatal beta-oxidation defect. Ann Neurol 1996; 40 (4) 597-602
• 84 Liewluck T, Mundi MS, Mauermann ML. Mitochondrial trifunctional protein deficiency: a rare cause of adult-onset rhabdomyolysis. Muscle Nerve 2013; 48 (6) 989-991
• 85 den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 2002; 109 (1) 99-104
• 86 Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr 1999; 88 (3) 237-245
• 87 Tein I, Donner EJ, Hale DE, Murphy EG. Clinical and neurophysiologic response of myopathy and neuropathy in long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency to oral prednisone. Pediatr Neurol 1995; 12 (1) 68-76
• 88 Schatz UA, Ensenauer R. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population. J Inherit Metab Dis 2010; 33 (5) 513-520
• 89 Tein I, Haslam RH, Rhead WJ, Bennett MJ, Becker LE, Vockley J. Short-chain acyl-CoA dehydrogenase deficiency: a cause of ophthalmoplegia and multicore myopathy. Neurology 1999; 52 (2) 366-372
• 90 Turnbull DM, Bartlett K, Stevens DL , et al. Short-chain acyl-CoA dehydrogenase deficiency associated with a lipid-storage myopathy and secondary carnitine deficiency. N Engl J Med 1984; 311 (19) 1232-1236
• 91 Bhala A, Willi SM, Rinaldo P, Bennett MJ, Schmidt-Sommerfeld E, Hale DE. Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1995; 126 (6) 910-915
• 92 Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2012; 7: 68
• 93 Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 2010; 20 (11) 693-700
• 94 Campos Y, Huertas R, Bautista J , et al. Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy. Muscle Nerve 1993; 16 (7) 778-781
• 95 Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C (2) 77-85
• 96 Vielhaber S, Feistner H, Weis J , et al. Primary carnitine deficiency: adult onset lipid storage myopathy with a mild clinical course. J Clin Neurosci 2004; 11 (8) 919-924
• 97 Köller H, Stoll G, Neuen-Jacob E. Postpartum manifestation of a necrotising lipid storage myopathy associated with muscle carnitine deficiency. J Neurol Neurosurg Psychiatry 1998; 64 (3) 407-408
• 98 Zhang W, Miao J, Zhang G , et al. Muscle carnitine deficiency: adult onset lipid storage myopathy with sensory neuropathy. Neurol Sci 2010; 31 (1) 61-64
• 99 Sugai F, Baba K, Toyooka K , et al. Adult-onset multiple acyl CoA dehydrogenation deficiency associated with an abnormal isoenzyme pattern of serum lactate dehydrogenase. Neuromuscul Disord 2012; 22 (2) 159-161
• 100 Rosenbohm A, Süssmuth SD, Kassubek J , et al. Novel ETFDH mutation and imaging findings in an adult with glutaric aciduria type II. Muscle Nerve 2014; 49 (3) 446-450
• 101 Wang ZQ, Chen HJ, Murong SX , et al. Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A. J Mol Med (Berl) 2011; 89 (6) 569-576
• 102 Zhao ZN, Bao MX, Ma GT , et al. A case of late-onset riboflavin responsive multiple acyl-CoA dehydrogenase deficiency with novel mutations in ETFDH gene. CNS Neurosci Ther 2012; 18 (11) 952-954
• 103 Prasad M, Hussain S. Glutaric aciduria type II presenting as myopathy and rhabdomyolysis in a teenager. J Child Neurol 2015; 30 (1) 96-99
• 104 Liang WC, Ohkuma A, Hayashi YK , et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord 2009; 19 (3) 212-216
• 105 Fiorillo C, Brisca G, Cassandrini D , et al. Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene. Biochem Biophys Res Commun 2013; 430 (1) 241-244
• 106 Reilich P, Horvath R, Krause S , et al. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. J Neurol 2011; 258 (11) 1987-1997
• 107 Kaneko K, Kuroda H, Izumi R , et al. A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy: a case report and literature review. Neuromuscul Disord 2014; 24 (7) 634-641
• 108 DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013; 9 (8) 429-444
• 109 Downham E, Winterthun S, Nakkestad HL , et al. A novel mitochondrial ND5 (MTND5) gene mutation giving isolated exercise intolerance. Neuromuscul Disord 2008; 18 (4) 310-314
• 110 Kollberg G, Moslemi AR, Lindberg C, Holme E, Oldfors A. Mitochondrial myopathy and rhabdomyolysis associated with a novel nonsense mutation in the gene encoding cytochrome c oxidase subunit I. J Neuropathol Exp Neurol 2005; 64 (2) 123-128
• 111 Milone M, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab 2013; 110 (1–2) 35-41
• 112 Giordano C, Pichiorri F, Blakely EL , et al. Isolated distal myopathy of the upper limbs associated with mitochondrial DNA depletion and polymerase gamma mutations. Arch Neurol 2010; 67 (9) 1144-1146
• 113 Peverelli L, Gold CA, Naini AB , et al. Mitochondrial myopathy with dystrophic features due to a novel mutation in the MTTM gene. Muscle Nerve 2014; 50 (2) 292-295
• 114 Blakely EL, Alston CL, Lecky B , et al. Distal weakness with respiratory insufficiency caused by the m.8344A > G “MERRF” mutation. Neuromuscul Disord 2014; 24 (6) 533-536
• 115 Liang C, Ahmad K, Sue CM. The broadening spectrum of mitochondrial disease: shifts in the diagnostic paradigm. Biochim Biophys Acta 2014; 1840 (4) 1360-1367
• 116 Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 2013; 81 (21) 1819-1826
• 117 Suomalainen A. Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. Expert Opin Med Diagn 2013; 7 (4) 313-317
• 118 Dubowitz V, Sewry C. Muscle Biopsy. A Practical Approach. Philadelphia, PA: Saunders Elsevier; 2007
• 119 Oglesbee D, Freedenberg D, Kramer KA, Anderson BD, Hahn SH. Normal muscle respiratory chain enzymes can complicate mitochondrial disease diagnosis. Pediatr Neurol 2006; 35 (4) 289-292
• 120 Wong LJ. Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion 2013; 13 (4) 379-387
• 121 Vasta V, Merritt II JL, Saneto RP, Hahn SH. Next-generation sequencing for mitochondrial diseases: a wide diagnostic spectrum. Pediatr Int 2012; 54 (5) 585-601
• 122 Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25 (3) 332-347